Perioperative celecoxib improves postoperative resting pain and active ROM after TKR .
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(2):48 BMC Musculoskelet Disord. 2008 Jun 3;9:77.80 patients scheduled to undergo total knee arthroplasty were randomized to receive celecoxib perioperatively along with the morphine PCA or just the morphine PCA. The purpose of this study was to evaluate efficacy of postoperative pain management. The perioperative celecoxib was found to significantly improve the postoperative resting pain scores at 48 and 72 hours and active ROM in the first three days after total knee arthroplasty. It also decreased the opioid consumption, without any increase in the occurrence of bleeding.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Oui = 1
Incertain = 0,5
Non pertinent = 0
Non = 0
L'évaluation des critères de rapport permet d'évaluer la transparence avec laquelle les auteurs rapportent les caractéristiques méthodologiques et les caractéristiques de l'essai dans la publication. L'évaluation est divisée en cinq catégories qui sont présentées ci-dessous.
2/4
Randomization
3/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
L'indice de fragilité est un outil qui aide à l'interprétation des résultats significatifs, en fournissant une mesure de la force d'un résultat. L'indice de fragilité représente le nombre d'événements consécutifs qui doivent être ajoutés à un résultat dichotomique pour que le résultat ne soit plus significatif. Un petit nombre représente un résultat plus faible et un grand nombre un résultat plus fort.
Pourquoi cette étude était-elle nécessaire maintenant ?
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most common medications chiefly used for multimodal pain management. Celecoxib is a newer selective COX-2 inhibitor with improved efficacy and lesser side effects. This study evaluated the opioid-sparing effects and post operative pain control after total knee arthroplasty.
Quelle était la principale question de recherche ?
How does oral celecoxib compare to patient controlled analgesia with morphine in post-operative pain management after total knee arthroscopy?
- Resting VAS pain scores improved significantly with the celecoxib compared to control treatment at 48 hrs (2.13
- +/- 1.68 vs. 3.43+/-1.50, p=0.03) and 72 hrs (1.78+/-1.66 vs. 3.17+/-2.01, p=0.02) after surgery. Moreover, the resting VAS pain reduction was more significant with celecoxib versus the control (p=0.023).
- Active ROM increased significantly in the celecoxib group, particularly in the first 72 hrs [40.8°+/-17.3° vs. 25.8°+/-11.5°, p=0.01 (day 1); 60.7°+/-18.1° vs. 45.0°+/-17.3°, p=0.004 (day 2); 77.7°+/-15.1° vs. 64.3°+/-16.9°, p=0.004 (day 3)]. Moreover, improvement in ROM was significantly greater with celecoxib versus the control (p=0.0009).
- With the celecoxib use, the opioid requirements (PCA morphine) decreased by 40% (p=0.03). Furthermore, the number of patients suffering from post-operative nausea/vomiting decreased from 43% in control group to 28% in celecoxib group - this was non significant (p=0.57).
- There were no differences in the perioperative blood losses between the groups; the patients on celecoxib had no greater requirement for blood transfusions.
De quoi dois-je me souvenir en priorité ?
The perioperative celecoxib was found to significantly improve the postoperative resting pain scores at 48 and 72 hrs and active ROM in the first three days after total knee arthroplasty, while decreasing the opioid consumption without any increase in the occurrence of bleeding.
Comment cela affectera-t-il les soins prodigués à mes patients ?
Celecoxib will serve as a good analgesic choice according to the study results. Caution should be exercised for their interpretation, keeping in mind the small sample size studied. The long-term effects require further research.
AVIS DE NON-RESPONSABILITÉ
Le contenu de cette page est fourni à titre d'information uniquement et n'est pas destiné à remplacer un avis médical, un diagnostic ou un traitement professionnel. Si vous avez besoin d'un traitement médical, demandez toujours l'avis de votre médecin ou rendez-vous au service des urgences le plus proche. Les opinions, croyances et points de vue exprimés par les individus sur le contenu de cette page ne reflètent pas les opinions, croyances et points de vue d'OrthoEvidence.
0 de 4 articles mensuels GRATUITS débloqués
